Project Grant R43CA171345

This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...

The National Cancer Institute awarded a $269,280 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Cold Spring Harbor Laboratory, a non-profit research institution. The grant supports the development of a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create prodrug molecules that can selectively degrade the K-RAS(G12C) protein and release cytotoxic polypharmaceuticals to concurrently target multiple pathways. The key...

The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, awarded a $188,351 Project Grant to The Ohio State University (OSU) to support research on identifying mutation-specific features, regulators, and combination therapy approaches for targeting KRAS oncoproteins in cancer. This 3-year grant will focus on studying the regulation of different KRAS mutations and evaluating the therapeutic potential of a novel pan-KRAS inhibitor discovered by the research...

The National Cancer Institute awarded a $406,500 Project Grant to Trethera Corp under the Cancer Treatment Research program (CFDA 93.395) to fund the development of a novel, targeted small molecule inhibitor called TRE-515. The goal is to establish the deoxycytidine kinase (DCK) enzyme as a targetable resistance mechanism for KRAS inhibitors in non-small-cell lung cancer (NSCLC) models. The research will evaluate the improved efficacy of KRAS inhibitors when combined with TRE-515 in KRAS-G12C...

This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mechanisms of resistance to KRAS G12C inhibitors in SMARCA4-mutant lung cancer. The $267,527 award will fund research at The University of Texas M.D. Anderson Cancer Center to: 1) Examine the molecular basis for reduced responsiveness to KRAS G12C inhibitors in SMARCA4-mutant lung cancer models, 2) Evaluate the potential of SMARCA2-targeting...

The University of Cincinnati was awarded a $162,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support research on "Targeting the HER Family in KRAS Mutant Colorectal Cancer". The grant aims to examine novel treatment strategies combining a KRAS inhibitor with a HER3 antibody-drug conjugate containing the payload exatecan. The 2-year project, running from July 1, 2025 to June 30, 2027, will explore how colorectal cancers with KRAS...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...

This Project Grant award, valued at $411,152, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant supports research at Duke University to identify and validate non-covalent interacting proteins of mutant KRAS inhibitors, which are critical for developing effective therapies for lung, pancreatic, and colorectal cancers driven by oncogenic KRAS mutations. The research aims to utilize mass spectrometry-based proteomics...

This $607,849 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research at Weill Medical College of Cornell University to investigate mechanisms of genetic and non-genetic resistance to KRAS inhibitor drugs for the treatment of lung and colorectal cancers. The research aims to define how cancer cells can develop resistance to KRAS-targeted therapies, including through inflammatory gene expression pathways. The project will...

The federal Cooperative Agreement award for "Next Generation T Cell Therapies for Mutant KRAS Solid Tumors" was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,238,704 award supports the early-stage clinical testing of a novel T cell receptor (TCR1020) therapy targeting the KRAS G12V mutation in solid tumors. The project aims to develop genetically modified T cells to overcome resistance mechanisms and promote durable tumor regression. Key...